427 related articles for article (PubMed ID: 26123705)
1. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
Ternant D; Bejan-Angoulvant T; Passot C; Mulleman D; Paintaud G
Clin Pharmacokinet; 2015 Nov; 54(11):1107-23. PubMed ID: 26123705
[TBL] [Abstract][Full Text] [Related]
2. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
[TBL] [Abstract][Full Text] [Related]
4. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
Pasut G
BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
[TBL] [Abstract][Full Text] [Related]
6. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
[TBL] [Abstract][Full Text] [Related]
7. A guide to rational dosing of monoclonal antibodies.
Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
[TBL] [Abstract][Full Text] [Related]
8. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
[TBL] [Abstract][Full Text] [Related]
9. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
Mori S
Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
[TBL] [Abstract][Full Text] [Related]
10. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.
Jinesh S
Inflammopharmacology; 2015 Jun; 23(2-3):71-7. PubMed ID: 25687751
[TBL] [Abstract][Full Text] [Related]
11. The underlying inflammatory chronic disease influences infliximab pharmacokinetics.
Passot C; Mulleman D; Bejan-Angoulvant T; Aubourg A; Willot S; Lecomte T; Picon L; Goupille P; Paintaud G; Ternant D
MAbs; 2016 Oct; 8(7):1407-1416. PubMed ID: 27589009
[TBL] [Abstract][Full Text] [Related]
12. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
St Clair EW; Wagner CL; Fasanmade AA; Wang B; Schaible T; Kavanaugh A; Keystone EC
Arthritis Rheum; 2002 Jun; 46(6):1451-9. PubMed ID: 12115174
[TBL] [Abstract][Full Text] [Related]
13. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
[TBL] [Abstract][Full Text] [Related]
14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
17. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
Boyce EG; Halilovic J; Stan-Ugbene O
Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
[TBL] [Abstract][Full Text] [Related]
18. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics.
Kurrasch R; Brown JC; Chu M; Craigen J; Overend P; Patel B; Wolfe S; Chang DJ
J Rheumatol; 2013 Jul; 40(7):1089-96. PubMed ID: 23729801
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
Frey N; Grange S; Woodworth T
J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
